Artificial intelligence-enabled clinical trials might be a faster way to perform rapid clinical trials and counter future pandemics: lessons learned from the COVID-19 period
- PMID: 36906740
- PMCID: PMC10389411
- DOI: 10.1097/JS9.0000000000000088
Artificial intelligence-enabled clinical trials might be a faster way to perform rapid clinical trials and counter future pandemics: lessons learned from the COVID-19 period
Conflict of interest statement
The authors declare that they have no financial conflict of interest with regard to the content of this report.
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Figures
References
-
- Lexchin J. Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic? Expert Opin Drug Discov 2021;16:475–479. - PubMed
-
- Fleming N. How artificial intelligence is changing drug discovery. Nature 2018;557:S55–S57. - PubMed
-
- Ringel MS, Scannell JW, Baedeker M, Schulze U. Breaking Eroom’s Law. Nat Rev Drug Discov 2020;19:833–834. - PubMed
-
- Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci 2019;40:577–591. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
